Trial · NCT00176930

Stem Cell Transplant for Hematological Malignancy

NCT00176930, Not applicable, Terminated, Masonic Cancer Center, University of Minnesota; results first posted 2021-01-22

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Stem Cell Transplant for Hematological Malignancy. Trials, record NCT00176930. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00176930

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Stem Cell Transplant for Hematological Malignancy
NCT number: NCT00176930
Status: Terminated
Phases: Not applicable
Enrollment: 330 participants, actual
Lead sponsor: Masonic Cancer Center, University of Minnesota
Conditions: Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MDS, Leukemia, Lymphocytic, Chronic, JMML, Hodgkin's Disease, Non-hodgkin's Lymphoma, Multiple Myeloma
Interventions: Stem Cell Transplant, Cyclophosphamide, Total Body Irradiation, Busulfan, Equine ATG (ATGAM), CD4+/CD25+ cells
First posted: 2005-09-15
Last updated: 2021-01-22
Results first posted: 2021-01-22

Source ClinicalTrials.gov

Registered outcomes10

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants Experiencing Disease-Free Survival at 2 Years Post Transplant	2 years	Disease-Free Survival is the length of time during and after medication or treatment during which the disease being treated (usually cancer) does not get worse. It is sometimes used as a metric to study the health of a person with a disease to try to determine how well a new treatment is working.
Primary	Number of Participants Experiencing Disease-Free Survival at 5 Years Post Transplant	5 years	Disease-Free Survival is the length of time during and after medication or treatment during which the disease being treated (usually cancer) does not get worse. It is sometimes used as a metric to study the health of a person with a disease to try to determine how well a new treatment is working.
Secondary	Number of Participants With Neutrophil Engraftment	Day 42	Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm\^3 (0.5 x 10\^9/L) or greater.
Secondary	Number of Participants With Acute Graft-versus-host Disease (GVHD)	Day 100	Acute Graft-Versus-Host Disease (aGVHD) is a severe short-term complication created by infusion of donor cells into a foreign host. Determine the incidence of grade II-IV acute graft-versus-host disease (GVHD) at day 100 post transplant. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria used for staging. Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.
Secondary	Number of Participants With Chronic Graft-Versus-Host Disease	1 year	Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host. Determine the incidence of chronic GVHD 1 year post transplant. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria. Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.
Secondary	Number of Participants With Persistence or Relapse of Malignancy at 2 Years Post Transplant	2 years	Defined as the return of disease after its apparent recovery/cessation. Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.
Secondary	Number of Participants With Persistence or Relapse of Malignancy at 5 Years Post Transplant	5 years	Defined as the return of disease after its apparent recovery/cessation. Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.
Secondary	Number of Participants Who Were Alive at 2 Year Post Transplant	2 years	The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer.
Secondary	Number of Participants Who Were Alive at 5 Year Post Transplant	5 years	The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer.
Secondary	Number of Participants Experiencing Engraftment Failure	Day 42	Graft failure is defined as not accepting donated cells. The donated cells do not make the new white blood cells, red blood cells and platelets.

Source ClinicalTrials.gov

Outcomes10

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Number of Participants Experiencing Disease-Free Survival at 2 Years Post Transplant	2 years	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Number of Participants Experiencing Disease-Free Survival at 5 Years Post Transplant	5 years	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Neutrophil Engraftment	Day 42	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Acute Graft-versus-host Disease (GVHD)	Day 100	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Chronic Graft-Versus-Host Disease	1 year	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Persistence or Relapse of Malignancy at 2 Years Post Transplant	2 years	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Persistence or Relapse of Malignancy at 5 Years Post Transplant	5 years	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Who Were Alive at 2 Year Post Transplant	2 years	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Who Were Alive at 5 Year Post Transplant	5 years	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Experiencing Engraftment Failure	Day 42	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group80

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number of Participants Experiencing Disease-Free Survival at 2 Years Post Transplant	PBSC: No TBI	4	Participants
Number of Participants Experiencing Disease-Free Survival at 2 Years Post Transplant	Marrow : No TBI	9	Participants
Number of Participants Experiencing Disease-Free Survival at 2 Years Post Transplant	UCB : No TBI	0	Participants
Number of Participants Experiencing Disease-Free Survival at 2 Years Post Transplant	UCB : No TBI/Bu/Cy/ATG	0	Participants
Number of Participants Experiencing Disease-Free Survival at 2 Years Post Transplant	PBSC	100	Participants
Number of Participants Experiencing Disease-Free Survival at 2 Years Post Transplant	Marrow	52	Participants
Number of Participants Experiencing Disease-Free Survival at 2 Years Post Transplant	Umbilical Cord Blood	2	Participants
Number of Participants Experiencing Disease-Free Survival at 2 Years Post Transplant	Co-Enroll From MT0403	2	Participants
Number of Participants Experiencing Disease-Free Survival at 5 Years Post Transplant	PBSC: No TBI	3	Participants
Number of Participants Experiencing Disease-Free Survival at 5 Years Post Transplant	Marrow : No TBI	9	Participants

1 to 10 of 80Source ClinicalTrials.gov

See all 80 results by group

Participant flow24

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	PBSC: No TBI	12
Overall Study	STARTED	Marrow : No TBI	13
Overall Study	STARTED	UCB : No TBI	1
Overall Study	STARTED	UCB : No TBI/Bu/Cy/ATG	1
Overall Study	STARTED	PBSC	213
Overall Study	STARTED	Marrow	85
Overall Study	STARTED	Umbilical Cord Blood	2
Overall Study	STARTED	Co-Enroll From MT0403	2
Overall Study	COMPLETED	PBSC: No TBI	12
Overall Study	COMPLETED	Marrow : No TBI	13

1 to 10 of 24Source ClinicalTrials.gov

See all 24 participant flow

Adverse events208

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Infection	Infections and infestations	PBSC: No TBI	10	12	37
other	Infection	Infections and infestations	Marrow : No TBI	9	13	32
other	Infection	Infections and infestations	UCB : No TBI	1	1	6
other	Infection	Infections and infestations	UCB : No TBI/Bu/Cy/ATG	1	1	4
other	Infection	Infections and infestations	PBSC	114	213	375
other	Infection	Infections and infestations	Marrow	54	85	169
other	Infection	Infections and infestations	Umbilical Cord Blood	1	2	2
other	Infection	Infections and infestations	Co-Enroll From MT0403	0	2	0
other	Pneumonia	Respiratory, thoracic and mediastinal disorders	PBSC: No TBI	5	12	14
other	Pneumonia	Respiratory, thoracic and mediastinal disorders	Marrow : No TBI	6	13	8

1 to 10 of 208Source ClinicalTrials.gov

See all 208 adverse events

Adverse event totals24

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	PBSC: No TBI	9	12
Total, all-cause mortality	Marrow : No TBI	4	13
Total, all-cause mortality	UCB : No TBI	1	1
Total, all-cause mortality	UCB : No TBI/Bu/Cy/ATG	1	1
Total, all-cause mortality	PBSC	113	213
Total, all-cause mortality	Marrow	31	85
Total, all-cause mortality	Umbilical Cord Blood	0	2
Total, all-cause mortality	Co-Enroll From MT0403	0	2
Total, other adverse events	PBSC: No TBI	12	12
Total, other adverse events	Marrow : No TBI	10	13

1 to 10 of 24Source ClinicalTrials.gov

See all 24 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00176930

GET https://conductscience.org/api/trials/v1/NCT00176930/results?page=2

API reference For AI assistants